Evaluation of Methyl-3,4 Dihydroxybenzoate for Renal Protection in Rat Model of Streptozotocin–Nicotinamide-Induced Diabetic Nephropathy

Authors

  • Heriniaina Luca Rakotonarivo
  • Eswar Kumar Kilari
  • M. Abdullah Harh
  • Kusumanchi N M Manikumari

Keywords:

diabetic nephropathy, Methyl-3, 4 Dihydroxybenzoate, streptozotocin, nephroprotection, antioxidant enzymes

Abstract

Diabetic nephropathy (DN) is a serious microvascular impediment accompanying with type 2 diabetes that is characterized by progressive kidney damage resulting from increased oxidative stress and metabolic disruption. Many studies have described the antioxidant activity of phenols; as such, it can be speculated that these compounds may be used to treat some of the complications of diabetes. In this context, the current study investigated the nephroprotective efficacy of Methyl-3,4 Dihydroxybenzoate (MDHDB) against streptozotocin-nicotinamide-induced diabetic nephropathy (DN) in Wistar rats. DN was developed in Wistar rats using streptozotocin (40 mg/kg) given intraperitoneally 15 min after nicotinamide (100 mg/kg) administration. After confirming the presence of diabetes, the rats were divided into four groups: normal control, disease control, or two experimental groups receiving MDHDB at either 200 mg/kg or 400 mg/kg. Fasting blood glucose (FBG), body weight, food intake and water intake were assessed. In addition, The renal function test and the lipid profile were done. The status of oxidative stress markers were also carried out in the renal tissue. Finally, the the histopathology of the kidney was analyzed. MDHDB treatment lead to a reduction of fasting blood glucose (FBG) ,HbA1c and the symptoms of polydipsia and anorexia were enhanced in diabetic rats. Both of the doses of MDHDB exhibited a dose-dependent repair of the renal function indicators in diabetic rats, with the highest dose (400 mg/kg) exhibiting significant decreases in serum creatinine, blood urea nitrogen, and total proteins. Therefore, the results of this investigation indicate that MDHDB exhibit nephroprotective effects against DN through its multiple mechanisms including antihyperglycemic activity, improvement of oxidative stress indicators, improvement of lipid metabolism, and maintenance of the structure of the kidneys..

Downloads

Download data is not yet available.

References

[1] Saeedi P, Petersohn I, Salpea P, et al. (2019). "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition". Diabetes Research and Clinical Practice. 157: 107843. doi:10.1016/j.diabres.2019.107843

[2] Kaur N, Kishore L, Singh R (2018). "Dillenia indica L. attenuates diabetic nephropathy via inhibition of advanced glycation end products accumulation in STZ-nicotinamide induced diabetic rats". Journal of Traditional and Complementary Medicine. 8 (1): 226–238. doi:10.1016/j.jtcme.2017.06.007

[3] Alicic RZ, Rooney MT, Tuttle KR (2017). "Diabetic kidney disease: challenges, progress, and possibilities". Clinical Journal of the American Society of Nephrology. 12 (12): 2032–2045. doi:10.2215/CJN.11491116

[4] Tuttle KR, Bakris GL, Bilous RW, et al. (2014). "Diabetic kidney disease: a report from an ADA Consensus Conference". Diabetes Care. 37 (10): 2864–2883. doi:10.2337/dc14-1296

[5] Forbes JM, Coughlan MT, Cooper ME (2008). "Oxidative stress as a major culprit in kidney disease in diabetes". Diabetes. 57 (6): 1446–1454. doi:10.2337/db08-0057

[6] Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K (2016). "Diabetes and kidney disease: role of oxidative stress". Antioxidants & Redox Signaling. 25 (12): 657–684. doi:10.1089/ars.2016.6664

[7] Singh R, Devi S, Gollen R (2015). "Role of free radical in atherosclerosis, diabetes and dyslipidemia: larger-than-life". Diabetes/Metabolism Research and Reviews. 31 (2): 113–126. doi:10.1002/dmrr.2558

[8] Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM (2005). "Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation". Glycobiology. 15 (7): 16R–28R. doi:10.1093/glycob/cwi053

[9] Brownlee M (2001). "Biochemistry and molecular cell biology of diabetic complications". Nature. 414 (6865): 813–820. doi:10.1038/414813a

[10] Han H, Cao A, Wang L, et al. (2017). "Huangqi decoction ameliorates streptozotocin-induced rat diabetic nephropathy through antioxidant and regulation of the TGF-β/MAPK/PPAR-γ signaling". Cellular Physiology and Biochemistry. 42 (5): 1934–1944. doi:10.1159/000479834

[11] Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes care. 2005 Jan 1;28(1):164-76.https://doi.org/10.2337/diacare.28.1.164

[12] Bae JH.SGLT2 Inhibitors and GLP-1 Receptors Agonist in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. Diabetes Metab J.2025 May;49(3):386-402.doi:10.4093/dmj.2025.0220.

[13] Valle-Velázquez E, Zambrano-Vásquez OR, Cortés-Camacho F, Sánchez-Lozada LG, Guevara-Balcázar G, Osorio-Alonso H. Naringenin ー A potential nephroprotective agent for diabetic kidney disease: A comprehensive review of scientific evidence. Biomolecules and Biomedicine. 2024 Dec 1;24(6):1441.doi:10.17305/bb.2024.10511.

[14] Kumar S, Sharma UK, Sharma AK, Pandey AK. Protective efficacy of Solanum xanthocarpum root extracts against free radical damage: phytochemical analysis and antioxidant effect. Cellular and Molecular Biology. 2012 Dec 22;58(1):174-81.

[15] Ullah N, Azam Khan M, Khan T, Ahmad W. Protective potential of Tamarindus indica against gentamicin-induced nephrotoxicity. Pharmaceutical Biology. 2014 Apr 1;52(4):428-34.doi: 10.3109/13880209.2013.840318.

[16] Singla K, Singh R (2020). "Nephroprotective effect of Curculigo orchioides in streptozotocin-nicotinamide induced diabetic nephropathy in Wistar rats". Journal of Ayurveda and Integrative Medicine. 11 (4): 399–404. doi:10.1016/j.jaim.2020.05.006

[17] Kishore L, Kaur N, Singh R (2017). "Nephroprotective effect of Paeonia emodi via inhibition of advanced glycation end products and oxidative stress in streptozotocin-nicotinamide induced diabetic nephropathy". Journal of Food and Drug Analysis. 25 (3): 576–588. doi:10.1016/j.jfda.2016.08.009

[18] Zhang Z, Zhou X, Zhou X, Xu X, Liao M, Yan L, Lv R, Luo H. Methyl 3, 4-dihydroxybenzoate promotes neurite outgrowth of cortical neurons cultured in vitro★. Neural regeneration research. 2012 May 5;7(13):971-7 .doi:10.3969/j.issn.1673-5374.2012.13.002.

[19] N. S. Aminah(2017). “Methyl-3,4-dihydroxybenzoate and 9-10-dihydrophenanthrene-2,4,7-triol two phenolic compounds from Dioscorea alata L. and their antioxidant activity”. AIP Conf. Proc. 21 1888 (1): 020050. doi.org/10.1063/1.5004327

[20] Cai L, Wang LF, Pan JP, Mi XN, Zhang Z, Geng HJ, Wang JH, Hu SH, Zhang W, Gao Q, Wu WT. Neuroprotective effects of methyl 3, 4-dihydroxybenzoate against TBHP-induced oxidative damage in SH-SY5Y cells. Molecules. 2016 Aug 22;21(8):1071.doi:10.3390/molecules21081071

[21] Szkudelski T (2012). "Streptozotocin-nicotinamide-induced diabetes in the rat: characteristics of the experimental model". Experimental Biology and Medicine. 237 (5): 481–490. doi:10.1258/ebm.2012.011372

[22] Masiello P, Broca C, Gross R, et al. (1998). "Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide". Diabetes. 47 (2): 224–229. doi:10.2337/diabetes.47.2.224

[23] OECD (2002). "Test No. 423: Acute Oral Toxicity – Acute Toxic Class Method". OECD Guidelines for the Testing of Chemicals, Section 4. Paris: OECD Publishing. doi:10.1787/9789264071001

[24] Szkudelski T.Streptozotocin-nicotinamide-induced diabtes in the rats. Characteristics of the experimental model. Experimental biologiy and medicine 237,no.5(2012):481-490.

[25] Kpemissi M, Eklu-Gadegbeku K, Veerapur VP, Negru M, Taulescu M, Chandramohan V, Hiriyan J, Banakar SM, Nv T, Suhas DS, Puneeth TA. Nephroprotective activity of Combretum micranthum G. Don in cisplatin induced nephrotoxicity in rats: In-vitro, in-vivo and in-silico experiments. Biomedicine & Pharmacotherapy. 2019 Aug 1;116:108961.https://doi.org/10.1016/j.biopha.2019.108961

[26] Palsamy P, Subramanian S (2011). "Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling". Biochimica et Biophysica Acta. 1812 (7): 719–731. doi:10.1016/j.bbadis.2011.03.008

[27] Kishore L, Kaur N, Singh R (2017). "Distinct biomarkers for early diagnosis of diabetic nephropathy". Current Diabetes Reviews. 13 (6): 598–605. doi:10.2174/1573399812666161207123007

[28] Beutler E (1984). Red Cell Metabolism: A Manual of Biochemical Methods. 3rd ed. Orlando: Grune & Stratton.doi :10.7326/0003-4819-75-6-985_1

[29] Darkazally AZ, Alnour A, Homsi S. Troxerutin effect on gastric ulcers induced by ketorolac in rats: Relation with oxidative stress. Heliyon. 2024 Oct 15;10(19.DOI: 10.1016/j.heliyon.2024.e38893

[30] Li X. Improved pyrogallol autoxidation method: a reliable and cheap superoxide-scavenging assay suitable for all antioxidants. Journal of agricultural and food chemistry. 2012 Jun 27;60(25):6418-24.doi: 10.1021/jf204970r

[31] Annouf YA, Al-Laham SH, Al-Shatti EY. Effect of Amlodipine on enteropathy induced by Indomethacin in rats. International Journal of Current Pharmaceutical Research. 2020;12(3):144-50.doi:10.22159/ijcpr.

[32] Patil NR, Rasal VP, Malabade RH. Screening of mandarin oil on indomethcin induced inflammatory bowel disease in wistar rats. Indian J. Pharm. Educ. Res. 2014 Oct 1;48:1-6.DOI: 10.5530/ijper.48.4s.1.

[33] Bhave AL, Bhatt JD, Hemavathi KG. Antiulcer effect of amlodipine and its interaction with H2 blocker and proton pump inhibitor in pylorus ligated rats. Indian journal of Pharmacology. 2006 Nov 1;38(6):403-7.doi :10.4103/0253-7613.28206.

[34] Mehenni C, Atmani-Kilani D, Dumarçcay S, PerinD, Gérardin P, Atmani D. Hepatoprotective and antidiabetic effect of Postacia lentiscus leaf and fruit extratc.J.Food Drug Anal. 2016;24(3):653-669.doi:10.1016/j.jfda.2016.03.002

[35] Ruch RJ, Cheng SJ, Klaunig JE (1989). "Prevention of cytotoxicity and inhibition of intercellular communication by antioxidant catechins isolated from Chinese green tea". Carcinogenesis. 10 (6): 1003–1008. doi:10.1093/carcin/10.6.1003

[36] Iorember FM. Malnutrition in chronic kidney disease. Frontiers in pediatrics. 2018 Jun 20;6:161.Strominger JL, Brobeck JR. A mechanism of regulation of food intake. The Yale Journal of Biology and Medicine. 1953 Apr;25(5):383.

[37] Umanath K, Lewis JB (2018). "Update on diabetic nephropathy: core curriculum 2018". American Journal of Kidney Diseases. 71 (6): 884–895. doi:10.1053/j.ajkd.2017.10.026

[38] Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF (2015). "Inflammatory cytokines in diabetic nephropathy". Journal of Diabetes Research. 2015: 948417. doi:10.1155/2015/948417

[39] American Diabetes Association (2021). "Standards of medical care in diabetes—2021". Diabetes Care. 44 (Suppl 1): S1–S232. doi:10.2337/dc21-Sint

[40] Ceriello A, Esposito K, Piconi L (2008). "Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients". Diabetes. 57 (5): 1349–1354. doi:10.2337/db08-0063

[41] Rani V, Deep G, Singh RK, Palle K, Yadav UC (2016). "Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies". Life Sciences. 148: 183–193. doi:10.1016/j.lfs.2016.02.002

[42] Kpemissi M, Potârniche AV, Lawson-Evi P, Metowogo K, Melila M, Dramane P, Taulescu M, Chandramohan V, Suhas DS, Puneeth TA, Vlase L. Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: in-vivo and in-silico experiments. Journal of Ethnopharmacology. 2020 Oct 28;261:113133.doi :10.1016/j.jep.2020.113133

[43] Kamel FO, Shagroud O, Ahmad MA, Abd El-Aziz GS, Burzangi AS, Bakhshwin D, Jamal M, Karim S. Agmatine ameliorates diabetes type 2-induced nephropathy in rats. Asian Pacific Journal of Tropical Biomedicine. 2024 Jan 1;14(1):8-16.doi :10.1097/APT.0000000000000455.

[44] Mima A (2022). "Mitochondria-targeted drugs for diabetic kidney disease". Antioxidants. 11 (12): 2334. doi:10.3390/antiox11122334

[45] Pedersen LR, Olsen RH, Anholm C, Astrup A, Eugen-Olsen J, Fenger M, Simonsen L, Walzem RL, Haugaard SB, Prescott E. Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial. Cardiovascular diabetology. 2019 Oct 1;18(1):127.DOI: 10.1186/s12933-019-0934-x

[46] Kashihara N, Haruna Y, Kondeti VK, Kanwar YS (2010). "Oxidative stress in diabetic nephropathy". Current Medicinal Chemistry. 17 (34): 4256–4269. doi:10.2174/092986710793348581

[47] Giacco F, Brownlee M (2010). "Oxidative stress and diabetic complications". Circulation Research. 107 (9): 1058–1070. doi:10.1161/CIRCRESAHA.110.223545

[48] Bahadoran Z, Mirmiran P, Azizi F (2013). "Dietary polyphenols as potential nutraceuticals in management of diabetes: a review". Journal of Diabetes and Metabolic Disorders. 12 (1): 43. doi:10.1186/2251-6581-12-43

[49] Kanwar YS, Sun L, Xie P, Liu FY, Chen S (2011). "A glimpse of various pathogenetic mechanisms of diabetic nephropathy". Annual Review of Pathology. 6: 395–423. doi:10.1146/annurev.pathol.4.110807.092150

[50] Mogensen CE, Christensen CK, Vittinghus E (1983). "The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy". Diabetes. 32 (Suppl 2): 64–78. doi:10.2337/diab.32.2.s64.

Downloads

Published

2026-02-13

How to Cite

1.
Rakotonarivo HL, Kilari EK, Harh MA, N M Manikumari K. Evaluation of Methyl-3,4 Dihydroxybenzoate for Renal Protection in Rat Model of Streptozotocin–Nicotinamide-Induced Diabetic Nephropathy. J Neonatal Surg [Internet]. 2026 Feb. 13 [cited 2026 May 24];15(1):124-42. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10001

Issue

Vol. 15 No. 1 (2026): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.